Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Issues in Oncology

The ASCO Post Staff

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Deborah Schrag, MD, MPH, of Dana-Farber Cancer Institute, offers her perspective on near-equivalence, Bayesian noninferiority, and the value of cancer drug optimization.

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Lymphoma

The ASCO Post Staff

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Mark J. Ratain, MD, of the University of Chicago, talks about why ibrutinib—which can lead to cardiotoxicities—should be studied at a lower dose for patients with chronic lymphocytic leukemia. Data suggest a reduced dose may prevent dose interruption due to adverse events and may have a better therapeutic index.

Jun

Today In Oncology

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

Related Videos

Amit Sanyal, MD: A Clinician’s Perspective

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Deborah Schrag, MD, MPH, on Clinical Trial Design: Statistical Options and Challenges

Leonard B. Saltz, MD, on the Future of Interventional Pharmacoeconomics

Mark J. Ratain, MD, on Chronic Lymphocytic Leukemia: Making a Case for Low-Dose Ibrutinib

Early Palliative Care Improves Quality of Life for Patients With Breast Cancer in India

Breast Cancer Palbociclib-Based Regimen Approved for HR-Positive, HER2-Positive Metastatic Disease

Advanced Breast Cancer Novel CDK4/6 Inhibitor Plus an Aromatase Inhibitor

FDA Approves Sacituzumab Govitecan-hziy as Monotherapy and in Combination With Pembrolizumab for First-Line Treatment of TNBC

Educational Gaps Found in Cardio-Oncology Training